Diagnosis of HCM With AI-ECG
Launched by SHANGHAI ZHONGSHAN HOSPITAL · Feb 29, 2024
Trial Information
Current as of April 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to diagnose hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes thickened, making it harder for the heart to pump blood. Researchers are using advanced technology called artificial intelligence (AI) to analyze electrocardiograms (ECGs), which are tests that measure the electrical activity of the heart. The goal is to create a model that can help doctors diagnose HCM more accurately and quickly.
If you or a loved one has been diagnosed with HCM and is between the ages of 65 and 74, you may be eligible to participate in this study. Unfortunately, those who have a specific type of heart device called a ventricular pacemaker cannot take part. Participants in the trial will undergo ECG tests enhanced by AI, and they will contribute to important research that could improve heart health for many people in the future. This study is currently recruiting, so there may be an opportunity to get involved and help advance understanding of this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with HCM
- Exclusion Criteria:
- • Patients with ventricular pacing
About Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital is a prestigious medical institution affiliated with Fudan University, renowned for its commitment to advancing healthcare through rigorous clinical research and innovative patient care. With a focus on multidisciplinary collaboration and cutting-edge medical technologies, the hospital conducts a wide range of clinical trials aimed at improving treatment outcomes across various specialties. Its state-of-the-art facilities and highly qualified research team ensure that trials adhere to the highest ethical and scientific standards, contributing significantly to the global body of medical knowledge and enhancing patient health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Yixiu Liang, MD
Principal Investigator
Fudan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported